Skip To Content

Error

Sorry, the page you're looking for has moved or doesn't exist.

You can access content using the navigation, searching or visiting the links provided on this page.

Articles and blogs 

April 13, 2022 · Medicare Insights Team
On March 28, 2022, a Sixth District Court (Southern District of Ohio Eastern Division) issued an Opinion and Order holding that Medicare Advantage Organizations (MAOs) have a private right of action for double damages under 42 U.S.C. § 1395y(b)(3)(A). Read more...
April 07, 2022 · Medicare Insights Team
On Wednesday, April 13, 2022, the Centers for Medicare and Medicaid Services (CMS) will host an overview of the new “Go Paperless” feature available in the Medicare Secondary Payer Recovery Portal (MSPRP). Read more...
March 29, 2022 · Medicare Insights Team
On March 15, the Centers for Medicare and Medicaid Services (CMS) released an updated Workers’ Compensation Medicare Set-Aside Arrangement (WCMSA) Reference Guide (Version 3.6). Read more...
March 23, 2022 · Public Policy & Regulatory Affairs Team
Read more...
March 09, 2022 · Public Policy & Regulatory Affairs Team
Read more...
March 08, 2022 · Medicare Insights Team
On March 1, 2022, Centers for Medicare and Medicaid Services (CMS) submitted the following two Rules to the White House Office of Regulatory Information and Affairs (OIRA) for review and approval. Read more...
February 24, 2022 · Public Policy & Regulatory Affairs Team
Read more...
February 21, 2022 · Medicare Insights Team
In response to the most recent Workers’ Compensation Medicare Set Aside (WCMSA) Reference Guide, on February 17, 2022, The Centers for Medicare and Medicaid Services (CMS) hosted a webinar to provide a much-anticipated update on non-CMS-approved Medicare Set-Aside (MSA) products. CMS’ John Jenkins, Health Insurance Specialist, reviewed topics including Evidence-Based MSAs, Non-Submit MSAs and Compromise MSA. Read more...
February 17, 2022 · Clinical Team
The U.S. Food and Drug Administration (FDA) issued a warning on January 12, 2022, regarding a potential risk of dental problems with orally-dissolving buprenorphine medications. Buprenorphine is a mixed opiate agonist-antagonist used to treat opioid use disorder (OUD) and pain. Read more...
February 17, 2022 · Clinical Team
The U.S. Food and Drug Administration (FDA) issued a warning on January 12, 2022, regarding a potential risk of dental problems with orally-dissolving buprenorphine medications. Buprenorphine is a mixed opiate agonist-antagonist used to treat opioid use disorder (OUD) and pain. Read more...
<< Previous      Next >>
Page 2 of 15